potential COVID-19 treatments - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.92 [0.88, 0.97]< 123%90 studies (90/-)100.0 %some concerncritical moderatecrucial-
death or transfer to ICU 0.84 [0.62, 1.13]< 153%5 studies (5/-)87.2 %some concernserious moderatecrucial-
deaths 0.91 [0.88, 0.95]< 118%166 studies (166/-)100.0 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.88 [0.81, 0.96]< 143%35 studies (35/-)99.9 %some concerncritical moderatecrucial-
clinical deterioration 0.78 [0.66, 0.91]< 148%34 studies (34/-)99.9 %some concernlow moderateimportant-
clinical improvement 1.16 [1.08, 1.24]> 148%49 studies (49/-)100.0 %some concerncritical moderateimportant-
clinical improvement (14-day) 1.15 [1.00, 1.31]> 147%26 studies (26/-)97.6 %some concernlow moderateimportant-
clinical improvement (21-day) 2.09 [0.04, 119.96]> 10%1 study (1/-)63.7 %NAnot evaluable important-
clinical improvement (28-day) 1.28 [1.12, 1.46]> 141%22 studies (22/-)100.0 %some concerncritical moderateimportant-
clinical improvement (7-day) 1.21 [1.02, 1.43]> 153%17 studies (17/-)98.5 %some concerncritical moderateimportant-
clinical improvement (time to event analysis only) 1.16 [1.09, 1.24]> 124%28 studies (28/-)100.0 %some concerncritical moderateimportant-
death or ventilation 0.92 [0.88, 0.97]< 153%37 studies (37/-)99.9 %some concerncritical moderateimportant-
hospital discharge 1.03 [0.99, 1.08]> 153%28 studies (28/-)94.0 %some concernlow moderateimportant-
hospitalization 1.58 [0.92, 2.70]< 10%2 studies (2/-)4.8 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.88 [0.81, 0.96]< 125%54 studies (54/-)99.9 %some concerncritical moderateimportant1
mechanical ventilation (time to event analysis only) 0.79 [0.47, 1.33]< 122%5 studies (5/-)81.2 %some concernserious moderateimportant-
radiologic improvement (14-day) 2.13 [1.30, 3.50]> 121%6 studies (6/-)99.9 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.09 [0.01, 0.78]> 10%2 studies (2/-)1.5 %some concernnot evaluable moderateimportant-
viral clearance 1.86 [1.28, 2.69]> 178%16 studies (16/-)99.9 %some concerncritical moderateimportant-
viral clearance (time to event analysis only) 1.23 [0.91, 1.66]> 157%4 studies (4/-)91.3 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.97 [0.48, 1.93]> 193%13 studies (13/-)46.2 %some concernlow moderateimportant-
viral clearance by day 7 1.09 [0.88, 1.34]> 148%12 studies (12/-)78.7 %some concernlow moderateimportant-
ICU admission 0.82 [0.70, 0.95]< 16%29 studies (29/-)99.5 %some concerncritical moderatenon important-
Major thrombotic events or death 1.04 [0.80, 1.36]< 10%1 study (1/-)38.7 %NAnot evaluable non important-
off oxygenation 0.98 [0.64, 1.51]> 10%1 study (1/-)46.4 %NAnot evaluable non important-
recovery 1.12 [1.01, 1.23]> 133%14 studies (14/-)98.6 %some concerncritical moderatenon important-

safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %NAnot evaluable important-
cardiac arrest 1.92 [0.35, 10.49]< 10%1 study (1/-)22.7 %NAnot evaluable important-
composite safety outcome 1.56 [0.78, 3.11]< 10%1 study (1/-)10.3 %NAnot evaluable important-
related AE (TRAE) 1.26 [0.14, 11.07]< 10%2 studies (2/-)41.9 %some concernnot evaluable moderateimportant-
related SAE (TRSAE) 1.24 [0.50, 3.11]< 10%1 study (1/-)32.0 %NAnot evaluable important-
serious adverse events 0.99 [0.88, 1.12]< 118%46 studies (46/-)55.8 %some concernlow moderateimportant-
superinfection 0.70 [0.46, 1.07]< 153%4 studies (4/-)95.0 %lownot evaluable highimportant-
acute kidney injury 1.18 [0.44, 3.18]< 10%1 study (1/-)37.2 %NAnot evaluable non important-
adverse events 1.44 [1.20, 1.73]< 158%36 studies (36/-)0.0 %some concernlow moderatenon important-
arrhythmia 0.91 [0.72, 1.15]< 10%3 studies (3/-)78.1 %some concernnot evaluable moderatenon important-
deep vein thrombosis 0.62 [0.23, 1.64]< 10%2 studies (2/-)83.1 %some concernnot evaluable moderatenon important-
elevated liver enzymes 0.95 [0.29, 3.10]< 184%3 studies (3/-)53.6 %some concernnot evaluable moderatenon important-
hyperbilirubinemia 0.97 [0.48, 1.93]< 10%2 studies (2/-)53.8 %lownot evaluable highnon important-
long QT 2.39 [0.24, 23.87]< 180%2 studies (2/-)23.0 %some concernnot evaluable moderatenon important-
Major bleeding 1.75 [1.14, 2.69]< 10%4 studies (4/-)0.5 %some concernnot evaluable moderatenon important-
pulmonary embolism 0.82 [0.20, 3.29]< 10%2 studies (2/-)61.1 %some concernnot evaluable moderatenon important-
renal impairment 1.26 [0.95, 1.67]< 10%4 studies (4/-)5.6 %some concernnot evaluable moderatenon important-

AE of interest endpoints 00

Thromboembolic events 0.96 [0.73, 1.27]< 10%3 studies (3/-)60.5 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.